10/02/2018: X-Rx Announces Completion of IND-enabling Studies with X-165 for the Treatment of Idiopathic Pulmonary Fibrosis and other Fibrotic Indications

X-Rx, Inc., a privately held biotechnology company focused on applying its innovative drug development capabilities to the generation of novel small molecule therapeutics, today announced that it has completed IND-enabling studies with X-165, a potent orally available inhibitor of autotaxin, for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic indications.

10/26/2016: X-Rx and Mercachem Provide Update on Two Discovery-Stage Oncology Programs

X-Rx, Inc, a biotechnology company focused on the creation of small molecule drug candidates, and Mercachem BV, a leading chemistry CRO with expertise in medicinal and process chemistry, today reported progress with two discovery-stage oncology programs from the portfolio of X-Rx. The programs target Mcl1, an anti-apoptotic target that is over-expressed in many liquid and solid tumor types, and TAK1, a member of the mitogen-activated protein kinase family.


11/11/2015: X-Rx Announces Autotaxin Inhibitor Collaboration with Gilead Sciences

X-Rx, Inc. announced today that it has entered into an exclusive agreement with Gilead Sciences, Inc. to develop X-Rx’s proprietary small molecule autotaxin (ATX) inhibitors.  ATX plays a key role in maintaining tissue homeostasis and is upregulated in many diseases, including idiopathic pulmonary fibrosis (IPF). Inhibition of ATX leads to a reduction in lysophosphatidic acid production, which blocks signaling cascades that ultimately drive the development of fibrosis.